JP Morgan Chase
LKFT

JP Morgan Chase’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

JP Morgan Chase’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.2K Buy
1,320
+1,170
+780% +$33.2K ﹤0.01% 6519
2026
Q1 		$4.33K Sell
150
-89
-37% -$2.95K ﹤0.01% 6907
2025
Q4 		$7.82K Buy
239
+168
+237% +$5.42K ﹤0.01% 6726
2025
Q3 		$2.46K Buy
+71
New +$2.27K ﹤0.01% 6879
2025
Q2 		– Sell
-835
Closed -$22.4K – 7298
2025
Q1 		$21K Sell
835
-216
-21% -$5.46K ﹤0.01% 6136
2024
Q4 		$28.9K Sell
1,051
-1,136
-52% -$31.7K ﹤0.01% 6165
2024
Q3 		$63K Sell
2,187
-94
-4% -$2.56K ﹤0.01% 5907
2024
Q2 		$56.5K Sell
2,281
-2,120
-48% -$60.2K ﹤0.01% 5803
2024
Q1 		$142K Buy
4,401
+4,395
+73,250% +$163K ﹤0.01% 5521
2023
Q4 		$244 Sell
6
-3,656
-100% -$135K ﹤0.01% 7031
2023
Q3 		$127K Buy
3,662
+3,150
+615% +$123K ﹤0.01% 5342
2023
Q2 		$20.8K Buy
512
+13
+3% +$530 ﹤0.01% 5909
2023
Q1 		$19K Buy
499
+35
+8% +$1.44K ﹤0.01% 5981
2022
Q4 		$21K Sell
464
-497
-52% -$20.9K ﹤0.01% 5865
2022
Q3 		$41K Sell
961
-293,468
-100% -$15M ﹤0.01% 5609
2022
Q2 		$16.4M Sell
294,429
-5,281
-2% -$313K ﹤0.01% 1768
2022
Q1 		$18.6M Buy
299,710
+7,223
+2% +$442K ﹤0.01% 1825
2021
Q4 		$16.1M Buy
292,487
+220
+0.1% +$11.5K ﹤0.01% 2003
2021
Q3 		$15.4M Buy
292,267
+291,819
+65,138% +$17.3M ﹤0.01% 1983
2021
Q2 		$31K Buy
448
+414
+1,218% +$31.6K ﹤0.01% 5851
2021
Q1 		$3K Sell
34
-19
-36% -$1.75K ﹤0.01% 5908
2020
Q4 		$5K Buy
53
+37
+231% +$4.52K ﹤0.01% 5449
2020
Q3 		$2K Sell
16
-531
-97% -$88.5K ﹤0.01% 5383
2020
Q2 		$108K Sell
547
-26,302
-98% -$5.45M ﹤0.01% 4534
2020
Q1 		$5.26M Buy
26,849
+9,631
+56% +$2.07M ﹤0.01% 2219
2019
Q4 		$3.56M Sell
17,218
-18,408
-52% -$3.4M ﹤0.01% 2954
2019
Q3 		$5.44M Buy
35,626
+10,836
+44% +$1.78M ﹤0.01% 2639
2019
Q2 		$3.16M Buy
24,790
+20,395
+464% +$2.42M ﹤0.01% 3036
2019
Q1 		$518K Buy
+4,395
New +$443K ﹤0.01% 4196
2018
Q4 		– Sell
-3,553
Closed -$399K – 5765
2018
Q3 		$399K Buy
+3,553
New +$375K ﹤0.01% 4379
2018
Q1 		– Sell
-26,718
Closed -$2.5M – 5475
2017
Q4 		$2.5M Sell
26,718
-3,211
-11% -$304K ﹤0.01% 3180
2017
Q3 		$3.07M Buy
+29,929
New +$2.62M ﹤0.01% 2902

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase's LKFT Position: Q2 2026 in Review

JP Morgan Chase increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 780% in Q2 2026, buying an estimated $33.2K and bringing the position to 1,320 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6519.

JP Morgan Chase first reported a position in LKFT in Q3 2017 and has held it in 32 quarters since. The position peaked at $18.6M in Q1 2022. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • JP Morgan Chase held 1,320 shares of Lakefront Biotherapeutics American Depositary Shares worth $39.2K as of Q2 2026.
  • JP Morgan Chase bought 1,170 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $33.2K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6519 holding.
  • JP Morgan Chase first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2017 and has held it in 32 quarters since.
  • JP Morgan Chase's Lakefront Biotherapeutics American Depositary Shares position peaked at $18.6M in Q1 2022.
  • 76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.